Promising efficacy and tolerability in this small cohort of patients with treatment-resistant AD
Dual Therapy for Atopic Dermatitis: Lebrikizumab and JAK Inhibitors Used in Tandem for Treatment-Resistant Cases from the June issue highlights an emerging treatment strategy for patients with difficult-to-manage atopic dermatitis who continue to experience significant disease burden despite standard therapies. This Brief Communication explores the combined use of lebrikizumab and JAK inhibitors in treatment-resistant patients, demonstrating promising efficacy and acceptable tolerability in real-world clinical practice. As treatment options for moderate-to-severe atopic dermatitis continue to evolve, this article offers timely clinical insight into combination systemic therapy and its potential role in managing recalcitrant AD.
Read the full JDD article to examine the study methods, detailed findings, and how polymeric cleansing strategies might integrate with your approach to managing sensitive skin.
